236 studies on GIP-R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case report is highly significant as it identifies a potential rare but serious adverse event associated with tirzepatide use in a patient population not traditionally considered at high risk for ketoacidosis. It…
This review provides strong evidence supporting Tirzepatide's potential as a highly effective therapeutic agent for Metabolically Dysfunctional-Associated Steatohepatitis (MASH), addressing a critical unmet medical ne…
This study powerfully underscores the chronic nature of obesity and the significant challenge of weight regain following tirzepatide discontinuation, emphasizing that sustained pharmacological intervention may be nece…
This pooled analysis strongly suggests that Tirzepatide is a highly effective add-on therapy for patients with Type 2 Diabetes who are not achieving optimal glycemic control with basal insulin alone. The dual action a…
These findings are highly significant, as they demonstrate that Tirzepatide, a dual GLP-1/GIP receptor agonist, offers substantial benefits beyond glycemic control and weight loss, directly addressing critical cardiov…
This pilot study holds significant promise, as successful integration of weight management strategies could potentially improve treatment efficacy and long-term outcomes for endometrial cancer patients. If tirzepatide…
This pilot study is crucial for understanding Tirzepatide's potential as a targeted therapy for MASLD, a condition with limited effective treatment options. Positive findings could pave the way for larger, more defini…
This trial is critically important because it addresses a significant gap in our understanding of how tirzepatide performs in a vulnerable and growing patient group. The findings could establish a new therapeutic opti…
This real-world evidence suggests that Tirzepatide could be a safe and effective therapeutic option for managing obesity and type 2 diabetes in kidney transplant recipients, a population often excluded from major clin…
This study provides initial evidence that combining LY3457263 with tirzepatide could represent a more potent and effective strategy for treating obesity than existing monotherapies. The favorable safety profile and en…
If successful, this pilot study could pave the way for a novel pre-surgical intervention to improve outcomes for prostate cancer patients. Demonstrating the feasibility of tirzepatide-assisted weight loss could lead t…
If tirzepatide proves safe and effective, it could represent a significant therapeutic advancement for individuals with Type 1 Diabetes who struggle with obesity or overweight. Currently, there are limited pharmacolog…
This case report is crucial as it highlights a potential, albeit rare, adverse event associated with Tirzepatide that could have significant implications for patient safety and clinical practice. Given the widespread …
This study provides robust real-world evidence supporting the favorable cardiovascular safety profile of tirzepatide, particularly concerning heart failure and arrhythmias, in a diverse patient population. The consist…
This study provides crucial evidence that early intervention with tirzepatide and semaglutide can significantly mitigate the progression of atherosclerosis, a leading cause of morbidity and mortality worldwide. The ob…
This case report provides compelling preliminary evidence suggesting a novel therapeutic avenue for Tirzepatide beyond its established metabolic indications. The observed improvements in autonomic dysfunction and POTS…
This case highlights a rare but potentially life-threatening adverse event associated with Tirzepatide use, particularly in individuals without pre-existing diabetes. It underscores the critical importance of educatin…
This real-world evidence strongly reinforces the efficacy and safety of Tirzepatide for managing Type 2 Diabetes and associated metabolic abnormalities in a broader, more diverse patient population than typically seen…
The initiation of this Phase IV trial is a significant step, as it explores a novel therapeutic avenue for Idiopathic Intracranial Hypertension (IIH), a condition with limited effective treatments. Tirzepatide, known …
The finding that tirzepatide pharmacokinetics are not significantly altered by renal impairment is highly significant. This suggests that patients with kidney disease, including those with end-stage renal disease (ESR…
This study is critical because it directly addresses a common clinical scenario: how to optimize treatment for Type 2 Diabetes patients who may not be achieving their goals on existing GLP-1 RA therapy. The expected s…
This trial represents a paradigm shift in Type 1 Diabetes management, potentially transforming daily life for millions by simplifying insulin delivery and reducing mental burden. If successful, tirzepatide could enabl…
This case report holds significant clinical importance as it expands the known adverse event profile of Tirzepatide, alerting clinicians to the possibility of drug-induced liver injury. While such events are rare, rec…
This study provides critical early insights into the potential cardiovascular protective effects of Tirzepatide, even before the official results of SURPASS-CVOT are released. The predicted 23% MACE reduction is highl…
If successful, this study could highlight a novel therapeutic benefit of semaglutide beyond its established roles in glycemic control and weight management. Identifying an effective pharmacological intervention for di…
While specific numerical outcomes from this completed trial (NCT03882970) are not detailed in the provided record, the study's primary objective was to demonstrate the superior efficacy of tirzepatide in improving gly…
As an active study (NCT07417618) not yet recruiting, specific results are not available; however, based on existing clinical trial data and the known mechanisms of these drugs, the study is expected to reveal signific…
This case report is significant as it contributes to the emerging understanding of tirzepatide's potential adverse effects, specifically hepatotoxicity. The finding highlights the importance for clinicians to consider…
If BGM0504 demonstrates comparable or superior efficacy and safety to Tirzepatide, it could represent a significant advancement in the treatment landscape for obesity. A new therapeutic option would provide clinicians…
This Randomized Control Trial is highly significant as it explores a novel strategy to enhance the effectiveness of bariatric surgery, potentially offering a more robust solution for severe obesity. If successful, com…
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
This study is significant because it addresses the complex interplay between inflammatory bowel disease and metabolic health, a common but often unaddressed clinical challenge. The key implication is that a combined t…
This case report is significant because it raises awareness of a potentially novel adverse event associated with tirzepatide, a widely used and highly effective medication. If a causal link were established, it would …
This comprehensive meta-analysis provides compelling and robust evidence that GLP-1 and dual GIP/GLP-1 receptor agonists offer substantial and multifaceted benefits for obese patients with HFpEF, extending significant…
This research highlights the superior patient experience and satisfaction associated with switching to Tirzepatide over escalating Dulaglutide in Type 2 Diabetes management. These findings provide crucial real-world e…
This critical appraisal underscores a crucial safety consideration for tirzepatide, a widely used and highly effective medication for type 2 diabetes and obesity. The identified increased risk of biliary diseases nece…
The potential success of this combination therapy could represent a significant advancement in the treatment landscape for obesity and overweight. By potentially enhancing the already impressive effects of tirzepatide…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
The potential for tirzepatide, a dual GLP-1 and GIP receptor agonist, to effectively treat Binge-Eating Disorder alongside its established benefits for obesity represents a significant advancement in metabolic and psy…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
The withdrawal of this study means a potential avenue for exploring enhanced weight loss and metabolic improvements, particularly through muscle preservation with Bimagrumab alongside Tirzepatide's established effects…
This foundational Phase 1 study is crucial for the development of tirzepatide, providing essential data on its pharmacokinetics and safety in humans. Understanding how the drug is absorbed, distributed, metabolized, a…
This pilot study is critically important as it addresses a significant unmet medical need for safe and effective weight management in obese kidney transplant recipients. Successful outcomes could establish Tirzepatide…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
This study is incredibly significant because it seeks to confirm if tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for weight management, can directly improve long-term health outcomes beyond just…